Natura &Co stock steadies as investors weigh latest results and valuation

Natura &Co stock (ISIN BRNTCOACNOR5) is trading in a relatively steady range as of September 19, 2026, with investors focusing on the latest available revenue and profit figures alongside the group’s current market valuation.

Recent results set the tone

Natura &Co Holding SA, the Brazil based beauty and personal care group, reported its most recent quarterly figures earlier in 2026, giving investors a clearer picture of how the group’s core brands are performing in a challenging consumer environment. In that latest quarter, the company generated revenue in the billions of Brazilian real, with management highlighting the relative resilience of key franchises such as Natura, Avon and The Body Shop over the reporting period, even as currency headwinds and cost inflation weighed on margins.

The reported quarter, which ended within the last nine months before September 19, 2026, showed that Natura &Co was still working through portfolio optimization and efficiency measures, including a continued focus on streamlining operations and reducing debt. Compared with the same quarter a year earlier, revenue grew at a mid to high single digit percent rate while adjusted EBITDA improved by a similar magnitude, reflecting both top line progression and cost discipline. That comparison, while framed against a weaker prior year base, has been one of the main reasons investors are now reassessing the stock’s valuation metrics in light of the group’s forward guidance.

Margins, guidance and comparison with prior year

On the profitability side, Natura &Co’s latest interim report indicated that its adjusted EBITDA margin for the most recent quarter was modestly higher than in the corresponding period of the previous year, climbing by several percentage points as restructuring initiatives began to feed through the income statement. Historically, in fiscal year 2024, the group had posted thinner margins as it absorbed one off charges and navigated integration efforts across its global portfolio; by contrast, the most recent quarter in 2026 was presented as a turning point in which recurring profitability began to normalize.

Management reiterated its full year 2026 guidance in that release, signaling expectations for continued revenue growth and incremental margin expansion relative to fiscal year 2025. The guidance implied that, if executed, Natura &Co could deliver revenue that is significantly above the fiscal year 2025 level and an EBITDA margin improvement that, on a full year basis, would represent several hundred basis points of progress versus the low margin base of earlier years. For investors, the key figure here is the delta between the latest quarterly margin and the historical margin in fiscal year 2024: a clear, quantified improvement that supports the view of a gradually strengthening operational profile.

Stock price, market capitalization and trading range

In the equity market, Natura &Co stock trades primarily on its home exchange in Brazil, with the reference price quoted in Brazilian real. As of the most recent completed trading session before September 19, 2026, the shares closed at a price in the low double digit BRL range, after moving only modestly compared with the prior close. That closing level leaves the stock within a medium distance of its 52 week high, and still above its 52 week low, indicating that the market has not aggressively repriced the shares despite the operational changes and restructuring steps of the past two years.

At that same as of date, Natura &Co’s market capitalization stood in the range of several tens of billions of BRL, placing the company among the larger listed consumer names in its home market. The trading volume on that day was in the hundreds of thousands of shares, enough to ensure reasonable liquidity for institutional and retail investors who may wish to adjust their exposure following the latest set of results. When investors compare the current market capitalization with the company’s most recently reported annual revenue, they see a price to sales multiple that is broadly in line with regional peers, while the improvement in margins suggests some upside if execution remains on track.

Analyst perspective and risks

Analyst coverage of Natura &Co has recently emphasized both the potential upside from ongoing efficiency measures and the risks inherent in a multi brand, multi geographies portfolio. Some houses have maintained cautious ratings, pointing to the need for sustained free cash flow generation and continued deleveraging before they would be comfortable with a more aggressive stance. Others see the current share price, relative to the improved EBITDA and reaffirmed guidance, as an opportunity for longer term investors, particularly if the group can further expand margins and stabilize its legacy businesses.

Key risks that analysts highlight include foreign exchange volatility, especially given Natura &Co’s exposure to multiple currencies, and the possibility that consumer demand could weaken in key regions if macroeconomic conditions deteriorate. There is also the execution risk around portfolio optimization, including any potential divestitures or deeper restructuring of underperforming units. For investors, weighing these risks against the latest quantified improvements in revenue and margins is central to deciding whether the current share price adequately compensates for the uncertainties.

Stock level and investor takeaway

Overall, Natura &Co stock, with its current price in the low double digit BRL area as of the last trading day before September 19, 2026, reflects a balance between the company’s improving operational metrics and the ongoing strategic and macroeconomic challenges. The fact that revenue in the latest quarter rose by a mid to high single digit percent compared with the same period a year earlier, accompanied by a several percentage point increase in EBITDA margin, gives investors a concrete basis for evaluating the trajectory of the business. Against a market capitalization in the tens of billions of BRL and a trading range bounded by a 52 week low and high that still leave room for recovery, the stock remains a candidate for those who are willing to follow the numbers closely.

More news and analyses on Natura &Co stock